Established Cardiovascular Disease Guidelines Compared: ADA, AACE, Endocrine Society, and More

Published May 25, 2026Updated Sep 30, 2026Last reviewed May 25, 2026

13 linked public sourcesEditorial, sourcing, and corrections policy

The most useful guideline comparison starts with the condition being treated: atherosclerotic disease, heart failure, diabetes, or a combination. These conditions overlap, but their treatment pathways answer different questions. For established atherosclerotic cardiovascular disease (ASCVD), lowering LDL cholesterol and managing blood pressure remain central. Diabetes, kidney disease, heart failure, and weight then help determine which additional treatments fit. [1,2]

ASCVD includes atherosclerotic coronary disease, ischemic cerebrovascular disease, and peripheral arterial disease. Heart failure can coexist with ASCVD or arise from other causes. This distinction matters when comparing a cholesterol recommendation with a heart-failure recommendation.

LDL cholesterol: compare the document and the patient group

Guideline document	Population and LDL-C recommendation
ACC/AHA multisociety dyslipidemia guideline, 2026	In established ASCVD, LDL-C below 55 mg/dL for very-high-risk patients; below 70 mg/dL for those not at very high risk. [1]
ADA Standards of Care, 2026	In diabetes with ASCVD, high-intensity statin treatment aiming for at least a 50% LDL-C reduction and LDL-C below 55 mg/dL. [2]
AACE pharmacologic dyslipidemia guideline, 2025	Suggests LDL-C below 70 mg/dL for adults with dyslipidemia and ASCVD or increased ASCVD risk. [3]
Endocrine Society lipid guideline, 2020	In its type 2 diabetes recommendations, identifies LDL-C below 55 mg/dL for established CVD or multiple risk factors. [4]

These are recommendations from named documents with different publication dates and scopes. AACE's pharmacologic guideline should not be treated as interchangeable with every earlier AACE risk-category algorithm.

The 2026 multisociety guideline brings explicit LDL-C and non-HDL-C goals back into the treatment framework. Statins remain foundational; additional LDL-lowering medicines are selected according to the remaining gap, clinical risk, response, and tolerability. [1]

The Endocrine Society also identifies ezetimibe or a PCSK9 inhibitor as possible additions when statin treatment does not achieve the goal. It has a dedicated lipid guideline, rather than relying solely on its obesity-treatment guidance. [4]

Blood pressure: why the target may be more intensive

The 2025 ACC/AHA hypertension guideline uses a treatment goal below 130/80 mmHg for most adults. Existing cardiovascular disease is an important reason to treat elevated blood pressure promptly. [5]

ADA 2026 recommends an on-treatment goal below 130/80 mmHg when it can be attained safely and encourages a systolic goal below 120 mmHg in people with high cardiovascular or kidney risk. [2]

The diabetes-specific evidence now includes BPROAD. In 12,821 people with type 2 diabetes and elevated cardiovascular risk, targeting systolic pressure below 120 rather than below 140 reduced the primary cardiovascular outcome by 21% over a median 4.2 years. Achieved blood pressure and treatment tolerability both belong in the follow-up discussion. [6]

This is more precise than assuming every organization has one identical target for every patient.

GLP-1 treatment in people with and without diabetes

For type 2 diabetes with established ASCVD, ADA 2026 recommends an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit as part of the treatment plan. The decision addresses cardiovascular outcomes as well as glucose management. [2]

For established CVD with overweight or obesity without diabetes, semaglutide has direct outcomes evidence. The FDA approved Wegovy injection for reducing cardiovascular death, heart attack, and stroke in this population in March 2024. In the supporting trial, major cardiovascular events occurred in 6.5% with Wegovy and 8.0% with placebo. [7]

The 2023 ACC/AHA chronic coronary disease guideline also supports a GLP-1 receptor agonist for eligible patients with coronary disease and overweight or obesity when additional pharmacologic weight management is warranted. That recommendation addresses weight treatment; the subsequent cardiovascular indication is a separate, specific reason for prescribing. [8]

The Endocrine Society's older obesity pharmacotherapy guideline predates SELECT. Its general framework supports weight-management medication alongside lifestyle treatment for qualifying BMI and comorbidity profiles. SELECT findings should be attributed to the trial and later treatment indication, rather than retroactively inserted into that older guideline. [9]

SGLT2 inhibitors and heart failure

The AHA/ACC/HFSA heart-failure guideline includes SGLT2 inhibitors among the foundational medicine classes for symptomatic heart failure with reduced ejection fraction. Their use in that setting does not depend on having type 2 diabetes. [10]

DAPA-HF enrolled 4,744 people with heart failure and ejection fraction of 40% or less. Dapagliflozin reduced the combined outcome of worsening heart failure or cardiovascular death, with similar benefit in participants with and without diabetes. [11]

For someone with both ASCVD and heart failure, medication selection therefore needs to address both conditions. A GLP-1 medicine chosen for weight and atherosclerotic outcomes does not automatically replace a heart-failure regimen.

Antiplatelet treatment depends on the cardiovascular history

In chronic coronary disease without another indication for oral anticoagulation, the 2023 guideline recommends low-dose aspirin to reduce atherosclerotic events. A recent acute coronary syndrome or coronary stent introduces additional decisions about antiplatelet combinations. [8]

The 2025 acute coronary syndrome guideline uses aspirin plus a P2Y12 inhibitor for at least twelve months as the default after ACS when bleeding risk is not high. It also provides shorter or modified strategies for people whose bleeding risk or anticoagulation needs change the balance. [12]

Rivaroxaban plus aspirin is a selected long-term strategy, not a universal replacement for those post-ACS regimens. In COMPASS, low-dose rivaroxaban plus aspirin reduced cardiovascular events in stable atherosclerotic disease but increased major bleeding compared with aspirin alone. [13]

Does a calcium scan change established ASCVD treatment?

Coronary calcium testing is most useful for refining prevention decisions when risk is uncertain before clinical ASCVD is established. The 2026 lipid guideline's PREVENT risk framework is intended for people without known ASCVD or subclinical atherosclerosis. A person with a prior atherosclerotic event should be assessed using the secondary-prevention pathway. [1]

Put the comparison into a treatment review

Bring the latest lipid results, home blood-pressure record, medication list, and details of previous cardiovascular events. Useful questions are:

Which diagnosis and risk group drive my LDL goal?
Is the current medicine achieving that goal?
Does heart failure, diabetes, kidney disease, or weight change the next treatment choice?
What is the purpose and planned duration of each antiplatelet medicine?

These are questions for ongoing management. New chest pain, sudden one-sided weakness, difficulty speaking, or severe sudden breathlessness require emergency evaluation rather than waiting for a medication-review appointment.

References

Evidence overview for Established Cardiovascular Disease Guidelines Compared: ADA, AACE, Endocrine Society, and More